Reviva Pharmaceuticals Holdings Inc Ordinary Shares RVPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.48
- Day Range
- $0.41–0.50
- 52-Week Range
- $0.26–15.40
- Bid/Ask
- — / —
- Shares Outstanding
- 13.11M
- Market Cap
- $5.87M
- Volume/Avg
- 13,017 / 29,392
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 14
- Website
- https://www.revivapharma.com
Valuation
|
Metric
|
RVPH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.39 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVPH
|
|---|---|
Quick Ratio | 3.35 |
Current Ratio | 3.56 |
Interest Coverage | −2,049.61 |
Quick Ratio
RVPH
Profitability
|
Metric
|
RVPH
|
|---|---|
Return on Assets (Normalized) | −67.46% |
Return on Equity (Normalized) | −128.70% |
Return on Invested Capital (Normalized) | −130.15% |
Return on Assets
RVPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|rxcnhDb | LOCK|&<Nm | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>d&F%p | LOCK|lZkZ< | $83B | |||
| Moderna Inc
MRNA
| LOCK|&^wpckr | LOCK|ZlT | $80B | |||
| argenx SE ADR
ARGX
| LOCK|Gh<pPbH | LOCK|>^ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!>#?ws | LOCK|%M# | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qyXPm! | LOCK|DnxJK | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|pH#Yh^T | LOCK|NnvK? | $28B | |||
| Incyte Corp
INCY
| LOCK|WKRq?K | LOCK|yNZ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|lr!&m$ | LOCK|zK | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>@pW&< | LOCK|v> | $14B |
United States